Ensifentrine – complimentary MARA Rating report: pricing & reimbursement risk assessment for COPD maintenance therapy.
Ensifentrine, marketed as Ohtuvayre, has been reviewed under the MARA Rating system. This assessed its role in the maintenance treatment of chronic obstructive pulmonary disease (COPD). The overall MARA Score is 2.53 out of 4. This score corresponds to a Marginal (B++) rating. This places it below the 5-year therapeutic-area average (3.0). It is also below the industry-wide 5-year average (3.0). This reflects comparatively limited market-access strength.
Clinical Effectiveness: Very Strong Short-Term Results
Ensifentrine achieved very strong results in Phase 3 studies. Patients treated with the drug demonstrated significant short-term improvements in lung function (FEV1) and symptom scores versus placebo.
While these outcomes underline clear efficacy, the absence of long-term follow-up data beyond one year diminishes confidence in durability of benefit.
Comparator Selection: Appropriate but Limited
The trials adopted placebo plus standard care as the control, which is appropriate for establishing baseline efficacy. However, the lack of active comparator arms restricts the ability to directly position Ensifentrine against existing COPD therapies, limiting the strength of relative effectiveness insights.
Care-Pathway Integration: Strong Score with Pending Endorsements
Ensifentrine can be incorporated into current COPD management protocols without introducing new diagnostic testing or major shifts in monitoring requirements. Nonetheless, the fact that formal clinical guideline endorsements are still pending leaves some uncertainty regarding uptake and consistency in clinical practice.
About MARA Rating®
The MARA Rating synthesizes ten dimensions of market access risk – clinical efficacy, health-economic value, safety profile, comparator robustness, budget impact, and more – each scored on a seven-level scale (A++ to C).
We apply evidence-based weightings to generate a single risk score. A high MARA Score (A to A++) signals strong access prospects; a low score (B++ to C) denotes elevated pricing and reimbursement hurdles.
Unlock Premium Insights
Explore seven additional domains – Quality of Life (HRQoL), Cost-Effectiveness, Safety, Patient Population, Resource Use & Cost Implications, Evidence Quality, and Uncertainty – available exclusively in Premium Insights at mararating.com.
Full Premium Report available upon request: Visit mararating.com or email sales@mararating.com to learn more and unlock your access.
Access this report and hundreds of others: https://mararating.com/mara-ratings-list
Disclaimer: The MARA Rating® is an independent opinion of a drug’s market-access risk profile and is provided for informational purposes only – not as investment, medical, legal or any other type of advice. See our full disclaimer at mararating.com.